// App-Quantinova.ai

627 : Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study

Researchers

Presenter

  • Kristian Reich

Principal Investigators

  • Mark Goodfield

  • Lawrence Green

  • Kristine Nograles

  • Rongdean Chen

  • Eugenia Levi

  • Richard G.B. Langley

Medical Centers

  • Urologikum Hamburg, Hamburg, Germany

  • Leeds General Infirmary, Leeds, United Kingdom

  • George Washington University School of Medicine, Washington, DC

  • Celgene Corporation, Summit, NJ

  • Dalhousie University, Halifax, Nova Scotia, Canada.

Locations

  • Germany

  • United Kingdom

  • United States

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • N/A

Biomarkers

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • Apremilast

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved